8-K: Corvus Pharmaceuticals 2026 Annual Meeting Results
Annual Meeting Results
Corvus Pharmaceuticals stockholders re-elected directors, ratified auditors, and approved executive compensation at the 2026 Annual Meeting.
Summary
- Corvus Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 11, 2026.
- A total of 73,021,854 shares were voted out of 84,090,424 shares outstanding as of the April 16, 2026 record date.
- Stockholders elected Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. as Class I directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year.
- Stockholders approved the non-binding advisory vote on executive compensation.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine procedural filing that confirms standard corporate governance continuity.
Positives
- Successful quorum achieved with over 86% of outstanding shares represented at the meeting.
- Strong shareholder support for the board's director nominees.
- Overwhelming ratification of the independent accounting firm with 72,864,335 votes in favor.
- Clear majority approval for executive compensation packages.
Negatives
- None identified in this procedural filing.
Risks
- None identified in this procedural filing.
Future Outlook
The filing does not contain forward-looking financial guidance or strategic outlooks.
Industry Context
StockSavvy.ai notes that this filing represents standard annual corporate governance procedures for a clinical-stage biotechnology company, indicating stability in board composition and auditor relations.
Comparison to Industry Standards
- The voting participation rate of approximately 86.8% is consistent with typical engagement levels for small-cap biotechnology firms.
- The ratification of PricewaterhouseCoopers LLP aligns with standard practices for Nasdaq-listed life sciences companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. to the Board of Directors. | 2026-06-11 | Maintains board continuity and oversight. |
Stakeholder Impact
- Shareholders maintain continuity in board leadership and oversight.
- Company maintains established relationship with independent auditors.
Next Steps
- Directors will serve until the 2029 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 2026-04-16 | Record date for stockholders entitled to vote at the Annual Meeting. |
| 2026-04-24 | Filing date of the Definitive Proxy Statement on Schedule 14A. |
| 2026-06-11 | Date of the 2026 Annual Meeting of Stockholders. |
Keywords
Corvus Pharmaceuticals, CRVS, Annual Meeting, Proxy Voting, Corporate Governance, Shareholder Vote
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.